Relypsa relypsa.com


Public list: BIO 2016 (619) Pharma Startups (4740)

Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of non-absorbed polymeric drugs for applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of additional product candidates through use of its polymer platform.

Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of non-absorbed polymeric drugs for applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium bi...Show all

Company (Acquired)

Phone: 408-200-9500

Fax:

5301 Patrick Henry Drive

Santa Clara, 95054
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Relypsa $274.4M Jul 21, 2016
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Relypsa Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors

Competitors

Company Status Description Investors

Targacept

Winston-Salem, North Carolina, United States
IPO / Went publicTargacept is a biopharmaceutical company advancing NNR Therapeutics for the treatment of various diseases and disorders. The company's NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.Login to see details

Integral Molecular

Philadelphia, Pennsylvania, United States
Alive / ActiveIntegral Molecular develops technologies to enable the discovery and development of drugs that target integral membrane proteins, which are involved directly or indirectly in most major diseases, and comprise nearly half of all existing drug targets, including G protein-coupled receptors (GPCRs) and ion channels.Login to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Potassium-binding agents for treating hypertension and hyperkalemia Oct 06, 2016 Mar 27, 2018 Patent
Fluorination of acrylate esters and derivatives Oct 06, 2016 Aug 22, 2017 Patent
Amine polymers for use as bile acid sequestrants Feb 24, 2011 May 23, 2017 Patent
Potassium-binding agents for treating hypertension and hyperkalemia Dec 23, 2014 Nov 15, 2016 Patent
Fluorination of acrylate esters and derivatives Jun 17, 2015 Oct 11, 2016 Patent
See all 48 patents